Committed to helping Fight Disease
Reata’s lead candidates, bardoxolone methyl and omaveloxolone, are being developed for the treatment of a variety of chronic and genetic diseases for which a substantial unmet need exists. Our pipeline of therapeutics is focused in two main pillars: chronic kidney disease (CKD) and neurology, with late stage programs in Alport syndrome, autosomal dominant polycystic kidney disease (ADPKD), and Friedreich's ataxia.